Stockscreener 앱 받기
2.73
1.09%
-0.03
시간 외 거래:
2.29
-0.44
-16.12%
전일 마감가:
$2.76
열려 있는:
$2.74
하루 거래량:
7,229
Relative Volume:
0.04
시가총액:
$142.42M
수익:
$18.85M
순이익/손실:
$-119.67M
주가수익비율:
-1.3436
EPS:
-2.0318
순현금흐름:
$-89.09M
1주 성능:
+1.87%
1개월 성능:
+45.87%
6개월 성능:
-17.27%
1년 성능:
-30.00%
1일 변동 폭
$2.668
$2.77
1주일 범위
$2.60
$2.82
52주 변동 폭
$1.53
$4.75
인벤티바 Stock (IVA) Company Profile
인벤티바 Stock (IVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-10-27 | 개시 | Canaccord Genuity | Buy |
| 2023-05-31 | 개시 | ROTH MKM | Buy |
| 2023-05-19 | 업그레이드 | Societe Generale | Sell → Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2022-11-15 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2021-03-08 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 개시 | ROTH Capital | Buy |
| 2020-08-04 | 개시 | Guggenheim | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
인벤티바 주식(IVA)의 최신 뉴스
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewswire Inc.
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Inventiva ADR (IVA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - Inventiva
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketParamount ... - Benzinga
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and ... - GlobeNewswire Inc.
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
Assemblée Générale Mixte du 20 juin 2024 - GlobeNewswire Inc.
Inventiva's Key Drug Trial Advances PositivelyTipRanks.com - TipRanks
Inventiva SA ADR Announces Key General MeetingTipRanks.com - TipRanks
Inventiva's Lanifibranor Shows Promise in MASH/NASH TreatmentTipRanks.com - TipRanks
Inventiva announces the implementation of an At-The-Market program in the United States - The Globe and Mail
Inventiva's Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor EarningsTipRanks.com - TipRanks
Will Election Commission Make Sure That Elections In 2024 Will Be Completely Fair? - Inventiva
Inventiva SA ADR Announces Optimistic 2023 ResultsTipRanks.com - TipRanks
Inventiva’s LEGEND Trial Shows Promising Results - TipRanks
Is SBI's Demand For Extra Time To Disclose Details Of Electoral Bonds 1 Attempt To Hide The Doings And Doers Of ‘Great Political Chanda’? - Inventiva
IVA Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
National Parties Declare Assets Worth Rs 8,829 Crore In 2021-22: Report - Inventiva
Explosive Showdown: Rahul Yadav-Led 4B Networks Clash with Info Edge in High-Stakes Arbitration Battle - Inventiva
The Indian Chief Ministers Are A Bunch Of Crorepatis While The Average Middle-Class Indian Tax Payer Is Struggling To Survive - Inventiva
Top 10 Best Health & Wellness Companies In USA 2023 - Inventiva
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Top 10 Best Law Firms In India 2023. - Inventiva
Top 10 Best LegalTech companies in India 2023 - Inventiva
An Interesting Telecom Startup Announced Funding Of INR 30 Crore - Inventiva
TCS, Infosys, Wipro Hire Over 1 Lakh Employees This Fiscal. Know Details - Inventiva
8 US equities have commenced trading on the NSE IFSC in GIFT City; All information about how to start trading through IFSC and should you put money in US stocks? - Inventiva
Innovation And Technology Revolutionizing The Legal Landscape In India 2022 - Inventiva
India Has Its First Most Awaited International Arbitration Centre In Hyderabad In 2021. - Inventiva
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa - Yahoo Finance
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
인벤티바 (IVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):